SCIENTIFIC POSTERS

Search by category
3.3.2023 | Breast Cancer
Improved Sensitivity in Identification of ER and HER2 Expressing Metastatic Breast Cancer with a Combination of Cell & Cell-free Liquid Biopsy Analysis
12.10.2022 | Breast Cancer
A Single-Center Prospective Cohort Study to Evaluate Circulating Tumor Cells as a Monitoring Tool in Women with Breast Cancer Treated with Neoadjuvant Chemotherapy
12.9.2022 | Breast Cancer
TROP2 and HER2 Expression by Liquid Biopsy in Women with Metastatic Triple Negative Breast Cancer
12.9.2022 | Breast Cancer
Liquid Biopsy Identification of ERBB2 Amplified and HER2 Expressing Metastatic Breast Cancer: Comparison and Combination of Cell and Cell-free Platforms
12.9.2021 | Breast Cancer
Circulating tumor cells (CTCs), CTC heterogenity and distinct morphological CTC phenotypes predict worse survival in metastatic breast cancer (MBC)
2.11.2021 | Prostate Cancer
Development and Validation of Circulating Tumor Cell Enumeration (Epic Sciences) as a Prognostic Biomarker in Men with Metastatic Castration Resistant Prostate Cancer.
2.11.2021 | Prostate Cancer
CTC counts as a biomarker of prognosis and response in metastatic castration-resistant prostate cancer (mCRPC) from the CARD trial.
12.18.2020 | Breast Cancer
Pilot Trial of Priming With Oral TAK-228 and TAK-117 (PIKTOR) to Increase DNA Damage Repair Deficiency Followed By Cisplatin and Nab Paclitaxel in Chemotherapy-Pretreated Metastatic Triple Negative Breast Cancer Patients.
10.22.2020 | Prostate Cancer
Circulating Tumor Cells (CTCs) With Small-Cell Like Features are Prevalent in Metastatic Castration Resistant Prostate Cancer (mCRPC) and Show Selective Pharmacodynamic Reductions in Patients Treated With Platinum Therapy but not an ARSi or Taxane.
9.25.2020 | Prostate Cancer
Evaluating Biomarkers in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients (Pts) Treated with Enzalutamide (Enza): PSA, Circulating Tumor Cell Counts, AR-V7 Status, PET Imaging vs. CT and Tc99 Scans.
5.29.2020 | Prostate Cancer
Prevalence and tissue concordance of BRCA2 copy number loss evaluated by single-cell, shallow whole-genome sequencing of circulating tumor cells (CTCs) in castration-resistant prostate cancer (CRPC).
5.29.2020 | Prostate Cancer
Circulating tumor cells (CTCs) with small-cell like features are prevalent in metastatic castration resistant prostate cancer (mCRPC) and show selective pharmacodynamic reductions in patients treated with platinum therapy but not an ARSi or taxane.
5.29.2020 | Prostate Cancer
Clinical significance of CTC enumeration on the Epic Sciences platform in metastatic castration-resistant prostate cancer (mCRPC) patients treated with AR signaling inhibitors (ARSi).
5.26.2020 | Breast Cancer
Computer vision and machine learning allow for the prediction of genomic instability using circulating tumor cell morphology in triple negative breast cancer patients.
5.26.2020 | Breast Cancer
Phenotypic profiling of circulating tumor cells (CTCs) in patients with metastatic breast cancer reveals clinically-relevant heterogeneity in CTC morphology and marker expression.
6.10.2019 | Prostate Cancer
A phase 2 trial in progress: PAMIPARIB, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer and a circulating tumor cell homologous recombination deficiency phenotype or BRCA defects.
6.10.2019 | Prostate Cancer
Examination of the additive value of CTC biomarkers of Heterogeneity (Het) and Chromosomal Instability to Nuclear localized ( nl ) AR V7+ CTCs in prediction of poor outcomes to Androgen Receptor signaling inhibitor (ARSi) in Metastatic Castration Resistant Prostate Cancer (mCRPC).
6.10.2019 | Prostate Cancer
CTC vs. biopsy tissue sequencing: a concordance analysis of genomic copy number profile from mCRPC patients (pts).
4.19.2019 | IO
Simultaneous quantification of activated immune cells and PD-L1 expressing circulating tumor cells (CTCs) in peripheral blood of cancer patients receiving checkpoint inhibitor therapy.
4.19.2019 | Lung Cancer
SLFN11 and EZH2 protein expression and localization in circulating tumor cells to predict response or resistance to DNA damaging therapies in small cell lung cancer.
4.9.2019 | Breast Cancer
HER2, AR protein expression and chromosomal instability in circulating tumor cells (CTCs) of metastatic breast cancer (MBC) patients (pts).
12.6.2018 | Breast Cancer
Diverse Inter- and Intra-patient Circulating Tumor Cells (CTCs) Phenotypic Heterogeneity Identified in Metastatic Breast Cancer (MBC) Patients
12.6.2018 | Breast Cancer
Enabling detection of HER2 and AR protein expression and localization in circulating tumor cells (CTCs) of metastatic breast cancer (MBC) patients (pts)
11.16.2018 | Breast Cancer
Diverse Inter- and Intra-patient Circulating Tumor Cells (CTCs) Phenotypic Heterogeneity Identified Across Multiple Metastatic Breast Cancer (mBCa) Cohorts.
11.13.2018 | Lung Cancer
Measurement of SLFN11 protein in circulating tumor cells (CTCs) as a proposed liquid biopsy biomarker to predict response to DNA repair targeted therapies.
11.9.2018 | IO
Simultaneous quantification of activated immune cells and PD-L1 expressing circulating tumor cells (CTCs) in peripheral blood of cancer patients receiving checkpoint inhibitor therapy.
10.22.2018 | Prostate Cancer
Evaluation of the clinical utility of the nuclear-localized AR-V7 biomarker in CTCs in the context of physician intuition measured through physician therapy choice propensity and patient risk.
6.2.2018 | Prostate Cancer
Clonal Concordance and Genomic Heterogeneity in Single CTC Copy Number Alteration vs. Paired IMPACT Metastatic Tissue Sequencing from mCRPC Patient Samples.
6.2.2018 | Breast Cancer
Unique patterns of the Selection and Change in Circulating Tumor Cell (CTC) Phenotypes and Genotypes by Drug Class in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
6.2.2018 | Breast Cancer
Analysis of circulating tumor cells (CTCs) in patients across multiple metastatic breast cancer (mBCa) cohorts identifies marked inter- and intra-patient heterogeneity in CTC size, shape, and overall morphology.
6.2.2018 | Prostate Cancer
Phenotypic and genomic characterization of CTCs as a biomarker for prediction of Veliparib therapy benefit in mCRPC.
4.18.2018 | IO
Simultaneous Characterization and Quantification of Immune Cell Subpopulations and PD-L1 Expressing CTCs in Peripheral Blood of Cancer Patients.
4.17.2018 | FCP
Low Pass Whole Genome Sequencing of Single Circulating Tumor Cells for Detection of Chromosomal Instability (CIN) and Non-Coding Indels Across Multiple Solid Tumors.
4.15.2018 | Breast Cancer
Prediction of Genomic Instability (GI) in Triple Negative Breast Cancer (TNBC) Patients Utilizing a CTC Phenotype Classifier.
2.8.2018 | Prostate Cancer
Validation of Nuclear-Localized AR-V7 on Circulating Tumor Cells (CTC) as a Treatment-Selection Biomarker for Managing Metastatic Castration-Resistant Prostate Cancer (mCRPC).
2.8.2018 | Prostate Cancer
PSMA Heterogeneity Analysis in Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC): Imaging Versus CTCs.
10.27.2017 | FCP
Comprehensive single cell analysis of tumor mutation burden (TMB), chromosomal instability (CIN), and microsatellite instability (MSI) on circulating tumor cells (CTCs).
10.26.2017 | IO
Quantification of rare PD-L1 and other immunology biomarker expressing leukocytes and CTCs in peripheral blood of cancer patients.
10.17.2017 | Prostate Cancer
Glucocorticoid receptor (GR) expression in circulating tumor cells (CTCs) prognosticates poor overall survival (OS) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with androgen receptor signaling inhibitors (ARSi).
10.1.2017 | IO
Quantification of rare PD-L1 and other immunology biomarker expressing leukocytes and CTCs in peripheral blood of cancer patients.
9.9.2017 | Prostate Cancer
Phenotypic circulating tumor cell (CTC) classifier of genomic instability (GI) associates with improved overall survival (OS) for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving platinum agents in addition to taxanes.
6.2.2017 | Prostate Cancer
Changes in CTC burden and phenotypes in mCRPC patients (pts) receiving alpharadin (Ra-223) as single agent or in combination with other therapeutics (Tx).
6.2.2017 | Prostate Cancer
Baseline circulating tumor cell (CTC) subtype predicts responses to enzalutamide but not abiraterone in metastatic castration-resistant prostate cancer (mCRPC) patients.
4.7.2017 | Prostate Cancer
Integrated single cell phenogenomic subtyping of CTCs identify inter-cellular tumor heterogeneity (het) and multiple resistance mechanisms in mCRPC patients (pts).
4.3.2017 | Prostate Cancer
Phenotypic, genomic, and clinical associations of circulating tumor cells (CTCs) lacking epithelial biomarkers in metastatic castration resistant prostate cancer (mCRPC).
9.15.2016 | Prostate Cancer
Prediction of PARP inhibitor response and resistance utilizing a CTC phenotypic classifier in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the NCI 9012 trial.
6.3.2016 | Lung Cancer
Programmed death-1 ligand (PD-L1) expression on circulating CD45(-) cells is an independent prognostic factor for overall survival in patients with lung cancer.
6.3.2016 | Prostate Cancer
AR-V7 status and CTC heterogeneity improve the prediction of drug sensitivity and patient outcomes for taxanes and qpproved AR targeted therapies.
6.3.2016 | Prostate Cancer
CTC phenotype classifier identifies mCRPC patients with high genomic instability CTCs and predicts failure of Androgen Receptor signaling (AR Tx) and taxane systemic therapies.
4.17.2016 | Breast Cancer
Androgen receptor expression on circulating tumor cells (CTCs) in metastatic breast cancer.
4.16.2016 | Prostate Cancer
Validation of AR-V7 as a treatment-specific biomarker at decision points in management of castration-resistant prostate cancer.
1.8.2016 | Prostate Cancer
Single CTC characterization identifies phenotypic and genomic heterogeneity as a mechanism of resistance to AR signaling directed therapies (AR Tx) in mCRPC patients.
1.7.2016 | Prostate Cancer
Clinical validation of CTC subtype frequency to prognosis overall survival (OS) in metastatic castrate-resistant prostate cancer (mCRPC) patients.
1.7.2016 | Bladder Cancer
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.
1.7.2016 | Prostate Cancer
The use of whole genome copy number variation (CNV) to measure genomic instability in mCRPC CTCs.
1.4.2016 | Lung Cancer
Characterization of programmed cell death-1 ligand (PD-L1) expression in circulating tumor cells (CTCs) of lung cancer.
11.5.2015 | Colorectal Cancer
Single cell genomic profiling of circulating tumor cells (CTCs) from metastatic colorectal cancer (mCRC) identify tumor heterogeneity and rare somatic driver alterations.
5.29.2015 | Prostate Cancer
Intra-patient genomic heterogeneity of single circulating tumor cells (CTCs) associated to phenotypic CTC heterogeneity in metastatic castrate resistant prostate cancer (mCRPC).
5.29.2015 | FCP
Circulating tumor cell (CTC) detection and 5T4 characterization in breast, ovarian, and lung cancer patients on active therapy.
4.18.2015 | Prostate Cancer
Single cell analysis of AR N terminal, AR C terminal and the Arv7 splice variant in CTCs of metastatic castration resistant prostate cancer (mCRPC) patients.
4.18.2015 | Lung Cancer
The expression of fetal oncogene 5T4 in CTCs obtained from NSCLC patients is discordant with the expression measured in the primary tumor.
2.26.2015 | Bladder Cancer
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) and white blood cells (WBCs) in muscle invasive and metastatic bladder cancer patients.
11.18.2014 | Lung Cancer
Characterization of molecular targets of therapy in non-small cell lung cancer (NSCLC) utilizing a liquid biopsy.
11.18.2014 | Lung Cancer
Characterization of PD-L1 expression in circulating tumor cells (CTCs) of non-small cell lung cancer (NSCLC) patients.
9.26.2014 | Prostate Cancer
Characteristics of de novo resistance to androgen targeting therapeutics (AR Tx) through circulating tumor cells (CTCs) analysis in metastatic castration resistant prostate cancer (mCRPC) patients.
1.30.2014 | Prostate Cancer
Molecular characterization of circulating tumor cells (CTC) and CTC subpopulations in progressive metastatic castration resistant prostate cancer (mCRPC).
1.30.2014 | Bladder Cancer
Molecular characterization of circulating tumor cells (CTCs) of patients with neuroendocrine prostate cancer (NEPC).
1.6.2014 | Lung Cancer
Characterization of ALK fusions in circulating tumor cells (CTCs) of NSCLC.